The One-Two Combination

921

Metformin and troglitazone were both shown to improve glycemic control of type 2 diabetes. In addition, using them in combination proved to be safe and to provide additional benefit.

Two weeks after test subjects were taken off their anti-diabetic therapy (mostly sulfonylureas) they were put on metformin or troglitazone for three months (monotherapy).

After three months the subjects taking metformin had troglitazone added to their therapy (MET-TGZ), and the subjects taking troglitazone had metformin added (TGZ-MET). This combined therapy lasted for three more months. No significant side-effects or adverse effects were seen when the drugs were used in combination.

After three months of monotherapy, both groups experienced improved fasting blood sugars (FBS) levels. Metformin lowered FBS by 19 percent, and troglitazone lowered FBS by 17 percent. BG levels after a meal were also improved. BG response to a meal was decreased by 62 percent for patients on metformin and by 56 percent for patients taking troglitazone.

After three months of combined therapy, subjects experienced even more decreases in FBS. The MET-TGZ group’s FBS dropped (from baseline) 32 percent and the TGZ-MET group’s dropped 42 percent. In addition, HbA1c levels dropped 13.2 percent in the MET-TGZ group and 16 percent in the TGZ-MET group compared to HbA1cs on prior therapy.

Click here to view/write comments
Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.